October 21, 2023

From Chris Viehbach­er’s van­tage point, Bio­gen was nev­er re­al­ly a neu­ro­science com­pa­ny. Bio­gen has launched a sig­nif­i­cant re­vamp un­der Viehbach­er, in­clud­ing the re­cent hire of

Keytru­da’s pos­i­tive cer­vi­cal can­cer da­ta: Mer­ck said Fri­day that its pow­er­house can­cer drug re­duced the risk of dis­ease pro­gres­sion or death in ad­vanced cer­vi­cal can­cer

MADRID — Am­gen’s Phase II tri­al of its bis­pe­cif­ic T cell en­gager tar­latam­ab showed a re­sponse rate of 40% of pa­tients with small cell lung

John­son & John­son’s oral an­tivi­ral has shown hints of ac­tiv­i­ty in a Phase IIa hu­man chal­lenge tri­al for the pre­ven­tion of mos­qui­to-borne dis­ease dengue fever,

MADRID — Among the three an­ti­body-drug con­ju­gates from Mer­ck’s deal with Dai­ichi Sankyo, pa­tri­tum­ab derux­te­can takes up the largest por­tion of the $4 bil­lion up­front

→ Ex-Ole­ma On­col­o­gy chief Cyrus Har­mon has resur­faced as CEO of Vilya, a Seat­tle-based macro­cy­cle biotech from David Bak­er’s lab that raised a $50 mil­lion

MADRID — Including pembrolizumab (Keytruda) in the first-line treatment of metastatic HER2-positive gastric or gastroesophageal cancer improved progression-free survival (PFS), but potential harm was seen

Babies discharged from the emergency department (ED) for bronchiolitis saw mixed benefits from enhanced nasal suctioning, a randomized trial found. Additional resource use — a

A House hearing on ways to increase payments and cut red tape for physicians who treat Medicare patients also included a discussion over whether Republicans

Specialization in a single sport at a young age can lead to lasting negative health outcomes for children, including injury and burnout, said expert panelists